Hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML) patients has transitioned from the standard of care to a treatment option limited to those with unsatisfactory tyrosine kinase inhibitor (TKI) responses and advanced disease stages. In recent years, the threshold for undergoing HSCT has increased. Most CML patients now have life expectancies comparable to the general population, and therefore, the goal of therapy is shifting toward achieving treatment-free remission (TFR). While TKI discontinuation trials in CML show potential for achieving TFR, relapse risk is high, affirming allogeneic HSCT as the sole curative treatment. HSCT should be incorporated into treatment algorithms from the time of diagnosis and, in some patients, evaluated as soon as possible. In this review, we will look at some of the recent advances in HSCT, as well as its indication in the era of aiming for TFR in the presence of TKIs in CML.
对于慢性粒细胞白血病（CML）患者而言，造血干细胞移植（HSCT）已从标准治疗方案转变为仅限于对酪氨酸激酶抑制剂（TKI）反应不佳及疾病晚期患者的治疗选择。近年来，接受HSCT的治疗门槛有所提高。目前大多数CML患者的预期寿命已接近普通人群，因此治疗目标正转向实现无治疗缓解（TFR）。尽管CML的TKI停药试验显示出实现TFR的潜力，但复发风险仍然较高，这证实了异基因HSCT仍是目前唯一的根治性疗法。HSCT应自诊断之日起纳入治疗规划，并对部分患者尽快进行评估。本综述将探讨HSCT领域的最新进展，以及在CML患者接受TKI治疗并追求TFR的时代背景下，HSCT的适应症问题。
肿瘤(癌症)患者之家